Related Experiment Video
Updated: Jul 11, 2025
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Innovative Nanomaterials for Targeting Hypoxia to Improve Treatment for Triple-negative Breast Cancer
Suman Kumar Ray1, Sukhes Mukherjee2
1Independent Researcher, Bhopal, Madhya Pradesh, 462020, India.
Abstract:
Triple-negative breast cancer (TNBC) is an aggressive breast cancer with a high rate of metastases, a short overall survival time, and a poor response to targeted therapy. Improving tumor hypoxia by lowering the oxygen consumption rate of breast tumor cells is a powerful strategy. A viable way to address this issue is to improve therapeutic efficacy by improving the effectiveness of radiation and overcoming drug resistance in TNBC treatment by controlling hypoxia in the tumor microenvironment. The failure of radiation and chemotherapy in TNBC is frequently caused by hypoxia. In TNBC therapy, novel nanomaterials are used for oxygen delivery or generation to affect the tumor microenvironment to improve the effects of ionizing radiation using nanoplatforms. One of the growing fields is novel nano-based drug delivery devices for hypoxic regions and hypoxia- inducible factor-1 (HIF1) targeted therapeutics. Biocompatible nanoparticles may be used in the treatment of TNBC patients in the clinic. Because of the rising market and competition, intellectual property rights (IPR), patents, and tactics may be critically considered. To better comprehend the current state of IPR and patents in cancer nanotechnology, this overview examines recent advances and sophisticated protection measures in this area.
Insights
Triple-negative breast cancer (TNBC) treatment can be improved by controlling tumor hypoxia. Novel nanomaterials offer promising strategies for oxygen delivery and targeted therapies to enhance radiation and chemotherapy effectiveness.
Area of Science:
- Oncology
- Nanotechnology
- Biomedical Engineering
Background:
- Triple-negative breast cancer (TNBC) is aggressive, metastatic, and resistant to targeted therapies.
- Tumor hypoxia is a major challenge in TNBC, leading to treatment failure.
- Current treatments for TNBC often fail due to hypoxia-induced resistance to radiation and chemotherapy.
Purpose of the Study:
- To explore novel nanomaterial-based strategies for managing tumor hypoxia in TNBC.
- To review advancements in nanoplatforms for oxygen delivery and hypoxia-inducible factor-1 (HIF1) targeted therapeutics.
- To analyze the intellectual property landscape, including patents, for cancer nanotechnology relevant to TNBC.
Main Methods:
- Review of recent scientific literature on nanomaterials in TNBC therapy.
- Analysis of nanoplatforms designed for oxygen delivery and targeting hypoxic regions.
- Examination of intellectual property rights (IPR) and patent strategies in cancer nanotechnology.
Main Results:
- Novel nanomaterials are being developed for oxygen delivery to combat tumor hypoxia in TNBC.
- Nanoparticles show potential for targeted drug delivery in hypoxic tumor microenvironments.
- Biocompatible nanoparticles are emerging as viable clinical options for TNBC treatment.
Conclusions:
- Controlling tumor hypoxia via nanomaterials is a key strategy to improve TNBC treatment efficacy.
- Targeted nanotherapeutics offer a promising avenue for overcoming resistance in hypoxic TNBC.
- Understanding and leveraging intellectual property rights is crucial for advancing cancer nanotechnology in the clinic.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...